RESUMO
Hepatitis B virus (HBV) infection is considered a major public health problem worldwide, and a significant number of reports on nosocomial and occupational outbreaks have been reported. This systematic investigation of HBV stability and susceptibility to different antiseptics revealed that HBV infectivity was very stable, with a half-life of >22 days at 37°C. At 4°C, infectivity was barely reduced for up to 9 months. Different alcohols and commercially available hand antiseptics had a virucidal effect against HBV. We propose that very strict compliance with established hygienic guidelines should be mandatory to avoid and prevent HBV infections.
Assuntos
Anti-Infecciosos Locais/farmacologia , Infecção Hospitalar/prevenção & controle , Vírus da Hepatite B/efeitos dos fármacos , Hepatite B/prevenção & controle , Doenças Profissionais/prevenção & controle , 1-Propanol/farmacologia , 2-Propanol/farmacologia , Linhagem Celular , Infecção Hospitalar/virologia , Meio Ambiente , Etanol/farmacologia , Higiene das Mãos/normas , Higienizadores de Mão/farmacologia , Humanos , Concentração de Íons de Hidrogênio , Doenças Profissionais/virologia , Soro , Temperatura , Fatores de TempoAssuntos
Desinfecção/métodos , Contaminação de Equipamentos/prevenção & controle , Vírus da Hepatite B , Hepatite B , Temperatura Alta , Hepatite B/prevenção & controle , Hepatite B/virologia , Vírus da Hepatite B/isolamento & purificação , Vírus da Hepatite B/patogenicidade , Vírus da Hepatite B/fisiologia , Humanos , Controle de Infecções/métodosRESUMO
: Hepatitis C virus (HCV) infects ~71 million people worldwide, and 399,000 people die annually due to HCV-related liver cirrhosis and hepatocellular carcinoma. The use of direct-acting antivirals results in a sustained virologic response in >95% of patients with chronic HCV infection. However, several issues remain to be solved to eradicate HCV. At the 26th International Symposium on Hepatitis C Virus and Related Viruses (HCV2019) held in Seoul, South Korea, October 5-8, 2019, virologists, immunologists, and clinical scientists discussed these remaining issues and how we can achieve the elimination of HCV.